RFTN2

Across TCGA pan-cancer cohorts, RFTN2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of RFTN2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where RFTN2 RNA is repressed in tumor relative to normal tissue. In most cancer types RFTN2 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, HNSC, and LUSC are the cancer types where RFTN2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RFTN2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.572	<.001	9	view →
HNSC	All	III,IV	+0.531	.002	8	view →
LUSC	All	II,III,IV	−0.876	<.001	7	view →
KIRP	Male	All	−0.826	<.001	7	view →
BLCA	All	All	−0.575	.003	7	view →
UCEC	All	III,IV	−1.732	<.001	6	view →
LUAD	Female	III,IV	−0.954	<.001	6	view →
BRCA	All	II,III,IV	−0.634	<.001	6	view →
KICH	All	III,IV	−1.134	.001	5	view →
LIHC	All	All	+0.342	<.001	5	view →
CHOL	All	All	+0.447	.018	2	view →
PRAD	All	All	−0.228	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

RFTN2–THCA

Open the THCA breakdown →